achieved nameplate capacity, page-6

cmq doomed imu will capture this market with the help of Merial/

Our most advanced product, the Poultry Productivity Enhancer, has passed through several major milestones in its progress toward global commercialisation:

Commercial – finalisation of the Imugene sublicense in October 2005 granting Merial exclusive global rights to sell and distribute the Poultry Productivity Enhancer in return for a series of milestone licensing fees and royalty income on product sales.
Regulatory - Finalisation in September 2005 of regulatory dossier for the initial Australian regulator – the ‘OGTR’. Following their review of this dossier, the OGTR granted Imugene a licence now allowing the intentional release trial of the Poultry Productivity Enhancer outside of the laboratory. An Additional regulatory success was achieved with the receipt of a permit from the APVMA (Australian regulator of animal health products) to also conduct these trials.
Product Optimisation – the final stages of product development, being dose, timing, best method of manufacture and safety data, were all advanced in 2005 and have been handed over to the Merial product development team.
Background to the Poultry Productivity Enhancer Vaccine
Imugene’s patented vaccine boosts a natural component of the immune system, a cytokine known as gamma interferon. This boost to the immune system increases resistance to a range of bacterial as well as viral infections. Improved disease protection is provided for both gastrointestinal and respiratory diseases. Preventing these diseases improves growth rates, reduces mortality and reduces the costs of production (the major cost being feed).

Trials have demonstrated significant productivity improvement results:

Finishing Weight gains of 13.7% better than untreated birds and 15.8% above global industry best practice “Ross Standard”.
Improved feed conversion of 11.7% above the Ross Standard and 9.2% better than untreated birds.
Documented efficacy regardless of the presence or absence of in-feed antibiotics.
In addition to the outstanding efficacy results, Imugene’s vaccine is suitable for mass administration in water or feed.

The Competitive Advantages Over Antibiotics and Other Treatments
Imugene’s Poultry Productivity Enhancer also delivers other significant benefits over antibiotics and antimicrobial chemicals.

In-feed antibiotics are only effective against bacterial diseases and do not provide any protection against viral diseases whilst Imugene’s vaccine improves immune protection against both.
Imugene’s vaccine with its proven efficacy for improved feed conversion and weight gain, significantly lowers producers’ costs of production (i.e. shorter time period to market weight, lower feed costs).
Imugene’s products are biological (non-chemical) and are residue free, satisfying consumers’ increasing demands for antibiotic and chemical free chickens.
As the necessary regulatory approvals are obtained, the Poultry Productivity Enhancer vaccine will be sold across global poultry markets for use both with in-feed antibiotics and following their withdrawal. The product is ideally positioned to move into this expanding market.

Trial Results
The principal efficacy trial undertaken using the Poultry Productivity Enhancer demonstrated increased poultry growth of 13.7% and an 11.7% improvement in the Feed Conversion Ratio when compared to untreated birds. These weight gains exceed global industry best practice (The Ross Index) by up to 15.8%.